Bispebjerg Hospital

regionh.dk

Total trials

287

Active

40

Phase 3

6

Total enrollment

675,550

Read this sponsor's pipeline like an analyst.

Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.

~15-30 sec · cached for 24h

Pipeline matrix

Showing 14 of 14 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
Eplerenone1
Spironolactone1
Metoprolol Succinate1
Bisoprolol1
Carvedilol1
Nebivolol1
Sodium chloride2
Naproxen 500 Mg2
Corticosteroid1
Local anesthesia injections1
Semaglutide, 0.5 mg/mL1
Glucagon1
Glucagon+Exendin9-391
Growth hormone1

Next readouts

  • 2024-11-04
  • 2025-03
  • 2025-04-01
  • 2025-07-31
  • 2027-06-01
  • 2027-11-01
  • 2028-12-31

Top conditions

  • Asthma17
  • Sarcopenia9
  • Tendinopathy8
  • Obesity8
  • Stroke7
  • Cancer6
  • Hernia, Ventral6
  • Muscle Loss5

Frequently asked questions about Bispebjerg Hospital

How many clinical trials does Bispebjerg Hospital have on ClinicalTrials.gov?
Bispebjerg Hospital is listed as the lead sponsor on 287 clinical trials in ClinicalTrials.gov, 40 of which are currently active (recruiting, enrolling, or ongoing).
How many of Bispebjerg Hospital's trials are in Phase 3?
6 of Bispebjerg Hospital's trials are in Phase 3, spread across 14 active drug programs.
What therapeutic areas does Bispebjerg Hospital focus on?
Bispebjerg Hospital's most-studied conditions on ClinicalTrials.gov are Asthma, Sarcopenia, Tendinopathy, Obesity, Stroke.
When are Bispebjerg Hospital's next clinical trial readouts?
Bispebjerg Hospital has 7 upcoming primary-completion readouts tracked here; the soonest is “Resistance Training and Injection Treatment for Achilles Enthesopathy”, expected around 2024-11-04.